Atossa Therapeutics Inc. Common Stock (ATOS)

About ATOS

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other thera…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

16

Website

www.atossatherapeutics.com

Fundamentals

1-day range

$2.24$2.45

Market cap

$20.84M

P/E (trailing)

—

P/E (forward)

-0.54

EPS (trailing)

$-4.34

Dividend yield

—

Beta

1.25

Avg. volume

152.1K

Dividend pay date

April 20, 2018

Forecasts

3 analyst ratings

Atossa Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• ATOS

  Atossa Therapeutics Inc. Common Stock

  $2.58

  ▼ 2.27%
  Market cap $20.84MP/E —
  $1.7$19.35
• NEUP

  Neuphoria Therapeutics Inc. Common Stock

  $3.82

  ▲ 1.33%
  Market cap $21.08MP/E —
  $3.19$21.4
• CLRB

  Cellectar Biosciences Inc. Common Stock

  $2.54

  ▲ 0.00%
  Market cap $20.14MP/E —
  $2.2$6.52
• ALLR

  Allarity Therapeutics Inc. Common Stock

  $1.41

  ▲ 2.17%
  Market cap $21.65MP/E —
  $0.769$2.06
• DARE

  Dare Bioscience Inc. Common Stock

  $0.7437

  ▲ 0.64%
  Market cap $19.92MP/E —
  $0.73005$3.78
• GRDX

  GridAI Technologies Corp. Common Stock

  $4.05

  ▲ 1.00%
  Market cap $19.91MP/E —
  $1.73$6.93
• CALC

  CalciMedica Inc. Common Stock

  $0.4644

  ▼ 1.19%
  Market cap $21.88MP/E —
  $0.4606$7.2

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Atossa Therapeutics Q2 EPS $(0.95) Beats $(1.02) Estimate
  Benzinga · 8/7/2026

• Shu-Chih Chen · May 12, 2026 · Grant

  10.0K
• H. Lawrence Remmel · May 12, 2026 · Grant

  10.0K
• Jonathan Finn · May 12, 2026 · Grant

  10.0K
• Stephen J. Galli · May 12, 2026 · Grant

  10.0K
• Tessa Cigler · May 12, 2026 · Grant

  10.0K
• Richard I. Steinhart · May 12, 2026 · Grant

  10.0K
• Steven C. Quay · March 27, 2026 · Grant

  65.0K
• Mark James Daniel · March 26, 2026 · Grant

  63.0K

Institutional Ownership

March 31, 2026

Total shares held

1.24M

Total value held

$6.51M

Institutional holders

29